Loading clinical trials...
Loading clinical trials...
Due to the withdrawal of Thelin (Sitaxentan) in December 2010 all patients with pulmonary hypertension treated with Sitaxentan need to be switched to an alternative therapy. This study will observe in...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Heidelberg University
NCT06814145 · Hypertension, Pulmonary
NCT07079592 · Artificial Intelligence (AI), Artificial Intelligence (AI) in Diagnosis, and more
NCT05719415 · Hypertension, Pulmonary, Pulmonary Thromboembolisms
NCT01501838 · Hypertension, Pulmonary Arterial
NCT07039604 · Pulmonary Hypertension, Hypertension, Pulmonary Arterial
Department of Clinical Pharmacology and Pharmacoepidemiology, Medical department of the University of Heidelberg
Heidelberg, Baden-Wurttemberg
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions